Axsome Therapeutics Inc
AXSM
Market Cap$6.05B
Close$
$20.61
83.5% downside
Current Fair Value
83.5% downsideOvervalued by 83.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.05 Billion |
|---|---|
| Enterprise Value | $5.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.99 |
| Beta | 0.51 |
| Outstanding Shares | 49,442,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -24.29 |
|---|---|
| PEG | 61.42 |
| Price to Sales | 12.52 |
| Price to Book Ratio | 125.17 |
| Enterprise Value to Revenue | 12.05 |
| Enterprise Value to EBIT | -25.51 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 2.95 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...